|
1.
|
Gustafson P: Soft tissue sarcoma.
Epidemiology and prognosis in 508 patients. Acta Orthop Scand
(Suppl). 259:1–31. 1994.PubMed/NCBI
|
|
2.
|
Fletcher CD: Pleomorphic malignant fibrous
histiocytoma: fact or fiction? A critical reappraisal based on 159
tumors diagnosed as pleomorphic sarcoma. Am J Surg Pathol.
16:213–228. 1992. View Article : Google Scholar
|
|
3.
|
Isayama T, Iwasaki H and Kikuchi M: The
origin of malignant fibrous histiocytoma immunohistochemical
analysis with monoclonal antibodies. Medical Bulltein of Fukuoka
University. 14:191–203. 1987.
|
|
4.
|
Iwasaki H, Isayama T, Johzaki H and
Kikuchi M: Malignant fibrous histiocytoma. Evidence of perivascular
mesenchymal cell origin immunocytochemical studies with monoclonal
anti-MFH antibodies. Am J Pathol. 128:528–537. 1987.
|
|
5.
|
Iwasaki H, Yoshitake K, Ohjimi Y, et al:
Malignant fibrous histiocytoma. Proliferative compartment and
heterogeneity of ‘histiocytic’ cells. Am J Surg Pathol. 16:735–745.
1992.PubMed/NCBI
|
|
6.
|
Iwasaki H, Isayama T, Ohjimi Y, et al:
Malignant fibrous histiocytoma. A tumor of facultative histiocytes
showing mesenchymal differentiation in cultured cell lines Cancer.
69:437–447. 1992.
|
|
7.
|
Ellis SM, Nabeshima K and Biswas C:
Monoclonal antibody preparation and purification of a tumor cell
collagenase-stimulatory factor. Cancer Res. 49:3385–3391.
1989.PubMed/NCBI
|
|
8.
|
Yamamoto T, Marui T, Akisue T, et al:
Coexpression of hepatocyte growth factor and its receptor c-Met
correlates with high MIB-1 proliferative index in malignant fibrous
histiocytoma. Pathol Res Pract. 200:397–402. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Wallenius V, Hisaoka M, Helou K, et al:
Overexpression of the hepatocyte growth factor (HGF) receptor (Met)
and presence of a truncated and activated intracellular HGF
receptor fragment in locally aggressive/malignant human
musculoskeletal tumors. Am J Pathol. 156:821–829. 2000. View Article : Google Scholar
|
|
10.
|
Luan Y and Xu W: The structure and main
functions of aminopeptidase N. Curr Med Chem. 14:639–647. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Zhang X and Xu W: Aminopeptidase N
(APN/CD13) as a target for anti-cancer agent design. Curr Med Chem.
15:2850–2865. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Ishii K, Usui S, Sugimura Y, et al:
Aminopeptidase N regulated by zinc in human prostate participates
in tumor cell invasion. Int J Cancer. 92:49–54. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
13.
|
Ikeda N, Nakajima Y, Tokuhara T, et al:
Clinical significance of aminopeptidase N/CD13 expression in human
pancreatic carcinoma. Clin Cancer Res. 9:1503–1508. 2003.PubMed/NCBI
|
|
14.
|
Tokuhara T, Hattori N, Ishida H, et al:
Clinical significance of aminopeptidase N in non-small cell lung
cancer. Clin Cancer Res. 12:3971–3978. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15.
|
Mechtersheimer G and Moller P: Expression
of aminopeptidase N (CD13) in mesenchymal tumors. Am J Pathol.
137:1215–1222. 1990.PubMed/NCBI
|
|
16.
|
Mori A, Tagawa T, Kamei T, Murata T, Inui
M and Ohse S: Characterization of four cell lines derived from a
human malignant fibrous histiocytoma of the maxillary sinus. Oral
Oncol. 37:527–536. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
17.
|
Ichimura E, Yamada M, Nishikawa K, Abe F
and Nakajima T: Immunohistochemical expression of aminopeptidase N
(CD13) in human lung squamous cell carcinomas, with special
reference to Bestatin adjuvant therapy. Pathol Int. 56:296–300.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
18.
|
Gabrilovac J, Cupic B, Breljak D, Zekusic
M and Boranic M: Expression of CD13/aminopeptidase N and
CD10/neutral endopeptidase on cultured human keratinocytes. Immunol
Lett. 91:39–47. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
19.
|
Lai A, Ghaffari A and Ghahary A:
Inhibitory effect of anti-aminopeptidase N/CD13 antibodies on
fibroblast migration. Mol Cell Biochem. 343:191–199. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
20.
|
Mishima Y, Terui Y, Sugimura N, et al:
Continuous treatment of bestatin induces anti-angiogenic property
in endothelial cells. Cancer Sci. 98:364–372. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
21.
|
Pasqualini R, Koivunen E, Kain R, et al:
Aminopeptidase N is a receptor for tumor-homing peptides and a
target for inhibiting angiogenesis. Cancer Res. 60:722–727.
2000.PubMed/NCBI
|
|
22.
|
Saiki I, Fujii H, Yoneda J, et al: Role of
aminopeptidase N (CD13) in tumor-cell invasion and extracellular
matrix degradation. Int J Cancer. 54:137–143. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
23.
|
Fujii H, Nakajima M, Saiki I, Yoneda J,
Azuma I and Tsuruo T: Human melanoma invasion and metastasis
enhancement by high expression of aminopeptidase N/CD13. Clin Exp
Metastasis. 13:337–344. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
24.
|
Wulfanger J, Schneider H, Wild P, et al:
Promoter methylation of aminopeptidase N/CD13 in malignant
melanoma. Carcinogenesis. 33:781–790. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25.
|
Kido A, Krueger S, Haeckel C and Roessner
A: Inhibitory effect of antisense aminopeptidase N (APN/CD13) cDNA
transfection on the invasive potential of osteosarcoma cells. Clin
Exp Metastasis. 20:585–592. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
26.
|
Umezawa H, Aoyagi T, Suda H, Hamada M and
Takeuchi T: Bestatin, an inhibitor of aminopeptidase B, produced by
actinomycetes. J Antibiot (Tokyo). 29:97–99. 1976. View Article : Google Scholar : PubMed/NCBI
|
|
27.
|
Terauchi M, Kajiyama H, Shibata K, et al:
Inhibition of APN/CD13 leads to suppressed progressive potential in
ovarian carcinoma cells. BMC Cancer. 7:1402007. View Article : Google Scholar : PubMed/NCBI
|
|
28.
|
Tsukamoto H, Shibata K, Kajiyama H,
Terauchi M, Nawa A and Kikkawa F: Aminopeptidase N (APN)/CD13
inhibitor, Ubenimex, enhances radiation sensitivity in human
cervical cancer. BMC Cancer. 8:742008. View Article : Google Scholar : PubMed/NCBI
|
|
29.
|
Yamashita M, Kajiyama H, Terauchi M, et
al: Involvement of aminopeptidase N in enhanced chemosensitivity to
paclitaxel in ovarian carcinoma in vitro and in vivo. Int J Cancer.
120:2243–2250. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
30.
|
Zhang X, Zhang L, Zhang J, et al: Design,
synthesis and preliminary activity evaluation of novel
3-amino-2-hydroxyl-3-phenylpropanoic acid derivatives as
aminopeptidase N/CD13 inhibitors. J Enzyme Inhib Med Chem.
28:545–551. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
31.
|
Su L, Jia Y, Zhang L, Xu Y, Fang H and Xu
W: Design, synthesis and biological evaluation of novel amino acid
ureido derivatives as aminopeptidase N/CD13 inhibitors. Bioorg Med
Chem. 20:3807–3815. 2012. View Article : Google Scholar : PubMed/NCBI
|
